Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: May 20, 2008
Last updated: August 26, 2016
Last verified: August 2016
The purpose of this study is to define th Maximum Tolerated Dose (MTD) and the recommended dose (RD) of ZD6474 in combination with a fixed standard dose of gemcitabine and capecitabine

Condition Intervention Phase
Pancreatic Cancer
Drug: Vandetanib
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dose Escalation Study of the Combination of ZD6474, Gemcitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Define Maximum Tolerated Dose (MTD) [ Time Frame: during whole study ]
  • Define Recommended Dose (RD) [ Time Frame: during whole study ]

Secondary Outcome Measures:
  • Evaluate safety profile [ Time Frame: during whole study ]
  • Determine antitumour activity as determined by overall response rate (RR), progression free survival (PFS), disease control rate and duration of response [ Time Frame: every 2 months ]

Enrollment: 8
Study Start Date: July 2006
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Dose level 1
Vandetanib 100mg/day plus Gemcitabine
Drug: Vandetanib
Other Name: Zactima
Active Comparator: Dose level 2
Vandetanib 300mg/day plus Gemcitabine
Drug: Vandetanib
Other Name: Zactima
Active Comparator: Dose level 3
Vandetanib 100mg/day plus Gemcitabine plus CapecitabineDose
Drug: Vandetanib
Other Name: Zactima
Active Comparator: Dose level 4
Vandetanib 300mg/day plus Gemcitabine plus CapectiabineDose
Drug: Vandetanib
Other Name: Zactima


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of locally advanced unresectable or metastatic pancreatic adenocarcinoma
  • ECOG performance status <1
  • Measurable disease

Exclusion Criteria:

  • Severe or uncontrolled systemic disease
  • Clinically significant cardiac event such as myocardial infarction
  • Any concomitant medication that may cause OTc prolongation, include Torsades de Pointes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00681798

Research Site
St Gallen, SG, Switzerland
Research Site
Bellinzona, Switzerland
Sponsors and Collaborators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Additional Information:
Responsible Party: Sanofi Identifier: NCT00681798     History of Changes
Other Study ID Numbers: D4200L00003
Study First Received: May 20, 2008
Last Updated: August 26, 2016

Keywords provided by Sanofi:
pancreatic cancer
pancreatic adenocarcinoma
pancreas cancer
dose escalation study
locally advanced unresectable pancreatic adenocarcinoma

Additional relevant MeSH terms:
Pancreatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017